NLS Price Cash Flow Ratio vs Free Cash Flow Per Share Analysis

Stocks . USA . 
Stock . NLS Pharmaceutics AG
NLSPW Stock  USD 0.02  0.0001  0.62%   
NLS Pharmaceutics financial indicator trend analysis is infinitely more than just investigating NLS Pharmaceutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NLS Pharmaceutics is a good investment. Please check the relationship between NLS Pharmaceutics Price Cash Flow Ratio and its Free Cash Flow Per Share accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NLS Pharmaceutics AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

Price Cash Flow Ratio vs Free Cash Flow Per Share

Price Cash Flow Ratio vs Free Cash Flow Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NLS Pharmaceutics Price Cash Flow Ratio account and Free Cash Flow Per Share. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between NLS Pharmaceutics' Price Cash Flow Ratio and Free Cash Flow Per Share is -0.53. Overlapping area represents the amount of variation of Price Cash Flow Ratio that can explain the historical movement of Free Cash Flow Per Share in the same time period over historical financial statements of NLS Pharmaceutics AG, assuming nothing else is changed. The correlation between historical values of NLS Pharmaceutics' Price Cash Flow Ratio and Free Cash Flow Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price Cash Flow Ratio of NLS Pharmaceutics AG are associated (or correlated) with its Free Cash Flow Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Per Share has no effect on the direction of Price Cash Flow Ratio i.e., NLS Pharmaceutics' Price Cash Flow Ratio and Free Cash Flow Per Share go up and down completely randomly.

Correlation Coefficient

-0.53
Relationship DirectionNegative 
Relationship StrengthVery Weak

Price Cash Flow Ratio

Free Cash Flow Per Share

The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.
Most indicators from NLS Pharmaceutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NLS Pharmaceutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NLS Pharmaceutics AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
At this time, NLS Pharmaceutics' Selling General Administrative is fairly stable compared to the past year. Enterprise Value is likely to climb to about 1.1 B in 2024, whereas Issuance Of Capital Stock is likely to drop 0.00 in 2024.

NLS Pharmaceutics fundamental ratios Correlations

Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Long Term Debt
Cash And Short Term Investments
Common Stock Shares Outstanding
Non Current Liabilities Total
Capital Surpluse
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Total Current Assets
Net Working Capital
Common Stock
Net Receivables
Inventory
Short Long Term Debt
Total Assets
-0.330.08-0.040.89-0.78-0.460.070.96-0.25-0.25-0.330.960.22-0.340.30.130.62-0.630.420.990.610.530.13-0.310.46
Short Long Term Debt Total
-0.33-0.82-0.81-0.40.840.82-0.87-0.13-0.4-0.371.0-0.13-0.50.99-0.97-0.54-0.820.670.66-0.260.45-0.7-0.70.91-0.8
Other Current Liab
0.08-0.820.990.03-0.56-0.80.99-0.110.520.51-0.83-0.110.56-0.830.870.610.76-0.15-0.790.02-0.680.680.45-0.860.86
Total Current Liabilities
-0.04-0.810.99-0.05-0.49-0.730.99-0.230.590.58-0.83-0.230.5-0.820.870.570.68-0.13-0.86-0.11-0.760.60.49-0.850.81
Total Stockholder Equity
0.89-0.40.03-0.05-0.82-0.310.060.92-0.15-0.17-0.390.92-0.03-0.420.4-0.10.57-0.730.420.890.630.320.39-0.320.39
Net Debt
-0.780.84-0.56-0.49-0.820.74-0.58-0.65-0.14-0.110.84-0.65-0.360.84-0.82-0.35-0.870.810.15-0.73-0.1-0.69-0.590.76-0.77
Retained Earnings
-0.460.82-0.8-0.73-0.310.74-0.79-0.240.00.010.82-0.24-0.860.81-0.8-0.86-0.930.50.54-0.440.35-0.98-0.190.71-0.82
Accounts Payable
0.07-0.870.990.990.06-0.58-0.79-0.120.550.53-0.88-0.120.53-0.870.910.590.75-0.22-0.820.0-0.690.650.53-0.880.85
Cash
0.96-0.13-0.11-0.230.92-0.65-0.24-0.12-0.32-0.32-0.141.00.01-0.150.14-0.090.47-0.520.620.970.780.320.08-0.120.29
Non Current Assets Total
-0.25-0.40.520.59-0.15-0.140.00.55-0.321.0-0.43-0.32-0.32-0.420.43-0.210.00.07-0.54-0.35-0.56-0.160.7-0.670.39
Non Currrent Assets Other
-0.25-0.370.510.58-0.17-0.110.010.53-0.321.0-0.4-0.32-0.32-0.390.4-0.21-0.010.1-0.53-0.35-0.55-0.160.67-0.650.38
Long Term Debt
-0.331.0-0.83-0.83-0.390.840.82-0.88-0.14-0.43-0.4-0.14-0.491.0-0.98-0.53-0.820.660.66-0.260.46-0.69-0.690.93-0.82
Cash And Short Term Investments
0.96-0.13-0.11-0.230.92-0.65-0.24-0.121.0-0.32-0.32-0.140.01-0.150.14-0.090.47-0.520.620.970.780.320.08-0.120.29
Common Stock Shares Outstanding
0.22-0.50.560.5-0.03-0.36-0.860.530.01-0.32-0.32-0.490.01-0.460.460.980.68-0.25-0.490.23-0.380.91-0.23-0.320.5
Non Current Liabilities Total
-0.340.99-0.83-0.82-0.420.840.81-0.87-0.15-0.42-0.391.0-0.15-0.46-0.99-0.51-0.830.660.64-0.270.44-0.68-0.690.92-0.82
Capital Surpluse
0.3-0.970.870.870.4-0.82-0.80.910.140.430.4-0.980.140.46-0.990.510.85-0.56-0.650.24-0.440.670.68-0.910.85
Other Current Assets
0.13-0.540.610.57-0.1-0.35-0.860.59-0.09-0.21-0.21-0.53-0.090.98-0.510.510.66-0.23-0.590.14-0.480.87-0.18-0.40.56
Other Stockholder Equity
0.62-0.820.760.680.57-0.87-0.930.750.470.0-0.01-0.820.470.68-0.830.850.66-0.55-0.340.59-0.130.890.31-0.710.86
Total Liab
-0.630.67-0.15-0.13-0.730.810.5-0.22-0.520.070.10.66-0.52-0.250.66-0.56-0.23-0.550.05-0.61-0.18-0.47-0.50.48-0.36
Net Invested Capital
0.420.66-0.79-0.860.420.150.54-0.820.62-0.54-0.530.660.62-0.490.64-0.65-0.59-0.340.050.480.96-0.4-0.380.65-0.49
Total Current Assets
0.99-0.260.02-0.110.89-0.73-0.440.00.97-0.35-0.35-0.260.970.23-0.270.240.140.59-0.610.480.660.520.05-0.220.4
Net Working Capital
0.610.45-0.68-0.760.63-0.10.35-0.690.78-0.56-0.550.460.78-0.380.44-0.44-0.48-0.13-0.180.960.66-0.23-0.230.48-0.32
Common Stock
0.53-0.70.680.60.32-0.69-0.980.650.32-0.16-0.16-0.690.320.91-0.680.670.870.89-0.47-0.40.52-0.230.03-0.570.73
Net Receivables
0.13-0.70.450.490.39-0.59-0.190.530.080.70.67-0.690.08-0.23-0.690.68-0.180.31-0.5-0.380.05-0.230.03-0.720.39
Inventory
-0.310.91-0.86-0.85-0.320.760.71-0.88-0.12-0.67-0.650.93-0.12-0.320.92-0.91-0.4-0.710.480.65-0.220.48-0.57-0.72-0.88
Short Long Term Debt
0.46-0.80.860.810.39-0.77-0.820.850.290.390.38-0.820.290.5-0.820.850.560.86-0.36-0.490.4-0.320.730.39-0.88
Click cells to compare fundamentals

NLS Pharmaceutics Account Relationship Matchups

High Positive Relationship

Long Term Debt
+ 1.0
Short Long Term Debt Total
Cash And Short Term Investments
+ 1.0
Cash
Non Currrent Assets Other
+ 1.0
Non Current Assets Total
Non Current Liabilities Total
+ 1.0
Long Term Debt
Total Current Assets
+ 0.99
Total Assets
Non Current Liabilities Total
+ 0.99
Short Long Term Debt Total

High Negative Relationship

Capital Surpluse
- 0.99
Non Current Liabilities Total
Capital Surpluse
- 0.98
Long Term Debt
Common Stock
- 0.98
Retained Earnings
Capital Surpluse
- 0.97
Short Long Term Debt Total
Other Stockholder Equity
- 0.93
Retained Earnings
Inventory
- 0.91
Capital Surpluse

NLS Pharmaceutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets696.4K1.2M5.8M9.3M1.8M3.3M
Short Long Term Debt Total7.1M842.1K2.1M1.6M1.5M1.4M
Other Current Liab835.7K1.4M666.4K986.4K1.7M1.0M
Total Current Liabilities4.0M7.2M2.4M3.4M7.9M4.5M
Total Stockholder Equity(6.2M)(9.0M)542.4K3.3M(8.8M)(9.3M)
Net Debt621.9K2.0M(5.4M)(8.9M)736.1K772.9K
Retained Earnings(26.9M)(29.8M)(41.7M)(58.2M)(70.4M)(66.9M)
Accounts Payable2.5M4.0M1.7M2.4M4.6M2.7M
Cash220.3K93.7K5.4M8.9M897.7K852.8K
Non Current Assets Total314.7K1.0M41.6K30.2K23.6K22.4K
Non Currrent Assets Other260.2K946.9K12.0K12.1K16.9K16.0K
Cash And Short Term Investments220.3K93.7K5.4M8.9M897.7K852.8K
Common Stock Shares Outstanding11.1M4.8M14.7M19.7M38.2M40.1M
Liabilities And Stockholders Equity696.4K1.2M5.8M9.3M1.8M3.3M
Non Current Liabilities Total2.8M3.0M2.8M2.6M2.8M3.4M
Other Current Assets86.1K14.4K292.0K191.0K925.4K971.7K
Other Stockholder Equity20.6M20.6M42.1M60.9M61.0M35.5M
Total Liab6.9M10.2M5.2M6.0M10.7M6.6M
Net Invested Capital(5.3M)(6.9M)542.4K3.3M(7.2M)(6.8M)
Total Current Assets381.7K196.7K5.7M9.2M1.8M3.1M
Accumulated Other Comprehensive Income(18.7K)(19.4K)(151.7K)(50.8K)(158.1K)(150.2K)
Net Working Capital(3.7M)(7.0M)3.3M5.9M(6.1M)(5.8M)
Net Receivables75.4K61.2K38.6K41.2K10.7K10.1K
Inventory(33.6K)(61.2K)(38.6K)(41.2K)(37.1K)(39.0K)
Short Term Debt690.1K1.8M2.5B1.6M1.9M1.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
RSIRush Street Interactive
OKTAOkta Inc
BACBank of America

Additional Tools for NLS Stock Analysis

When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY